Abstract
Metabolic modulation has been an attractive therapeutic approach to heart failure as scientific evidence for an altered metabolic state in the failing heart has been demonstrated for decades. However, the ability to safely alter the substrate metabolism in the myocardium without adverse effects while at the same time be able to provide long-term benefits have not been widely investigated. Meanwhile, the ability to alter long-term molecular, cellular, and hormonal changes as a result of progressive cardiac dysfunction has been directly associated with improvement in clinical outcomes. Among the drugs that have been studied, glucagon-like peptide-1 (GLP-1) analogs and trimetazidine have demonstrated promise in this area. Data on GLP-1, although promising, remain to show short-term improvements. In contrast, trimetazidine has extensive long-term experience with favorable effects on reverse remodeling. However, the appropriate candidate to receive such therapies and the appropriate targets of therapy remain unclear, which may warrant further investigations.
Keywords: Remodeling, metabolic modulation, trimetazidine, glucagons-like peptide-1
Current Pharmaceutical Design
Title: The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Volume: 15 Issue: 8
Author(s): W.H. Wilson Tang
Affiliation:
Keywords: Remodeling, metabolic modulation, trimetazidine, glucagons-like peptide-1
Abstract: Metabolic modulation has been an attractive therapeutic approach to heart failure as scientific evidence for an altered metabolic state in the failing heart has been demonstrated for decades. However, the ability to safely alter the substrate metabolism in the myocardium without adverse effects while at the same time be able to provide long-term benefits have not been widely investigated. Meanwhile, the ability to alter long-term molecular, cellular, and hormonal changes as a result of progressive cardiac dysfunction has been directly associated with improvement in clinical outcomes. Among the drugs that have been studied, glucagon-like peptide-1 (GLP-1) analogs and trimetazidine have demonstrated promise in this area. Data on GLP-1, although promising, remain to show short-term improvements. In contrast, trimetazidine has extensive long-term experience with favorable effects on reverse remodeling. However, the appropriate candidate to receive such therapies and the appropriate targets of therapy remain unclear, which may warrant further investigations.
Export Options
About this article
Cite this article as:
Tang Wilson W.H., The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling, Current Pharmaceutical Design 2009; 15 (8) . https://dx.doi.org/10.2174/138161209787582138
DOI https://dx.doi.org/10.2174/138161209787582138 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology Mechanism of Oxidative Broncho-Epithelial Cell Damage with Reference to Gas Phase Cigarette Smoke
Mini-Reviews in Organic Chemistry Development of a Radiolabeled Amlodipine Analog for L-type Calcium Channel Imaging
Current Radiopharmaceuticals Hyponatraemia: An Audit of Aged Psychiatry Patients Taking SSRIs and SNRIs
Current Drug Safety Anti-Inflammatory Effects of Physical Activity in Relationship to Improved Cognitive Status in Humans and Mouse Models of Alzheimers Disease
Current Alzheimer Research Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design The Use of Colchicine in Respiratory Diseases
Current Respiratory Medicine Reviews Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Severe Psychiatric Disorders in Mid-Life and Risk of Dementia in Late- Life (Age 65-84 Years): A Population Based Case-Control Study
Current Alzheimer Research Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Heme Oxygenase-1/Carbon Monoxide: Novel Therapeutic Strategies in Critical Care Medicine
Current Drug Targets Accessing Timely Rehabilitation Services for a Global Aging Society? Exploring the Realities within Canadas Universal Health Care System
Current Aging Science Myocardial ‘No-Reflow’ Prevention
Current Vascular Pharmacology Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology New Analytical Method for Simultaneous Analysis of Losartan and E-3174 by HPLC in Human Plasma: Application in Pharmaceutical Science
Current Analytical Chemistry